Attached

July 24, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Outcome of Board Meeting held on July 24, 2026 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir/ Madam, Please take note that the Board of Directors in their meeting held today i.e. July 24, 2026, inter-alia considered the following(s): Financial Results 1. Approved un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30, 2026. A signed copy of the above Financial Results (Standalone & Consolidated) along with Limited Review Report issued by Statutory Auditors thereon under Regulation 33 of the Listing Regulations is attached herewith as “Annexure- A”. Interim Dividend 2. Approved declaration of Interim Dividend of INR 5/- per equity share (@ 50% on a face value of INR 10/- each) for the FY 2026-27. The record date for the purpose of payment of Interim Dividend shall be July 30, 2026. The Interim Dividend will be paid within 30 days of its declaration. Grant of Stock Options 3. Approved granting of Stock Options under Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 to eligible employees. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time is enclosed herewith as “Annexure – B”. Acquisition(s) 4. Took note that the Board of Dr Lal PathLabs FZCO, Dubai, Wholly Owned Subsidiary of the Company, approved acquisition of stake in Sunshine Healthcare Limited (“SHL”), Ghana. 5. Took note that the Board of Dr. Lal Ventures Private Limited, Wholly Owned Subsidiary of the Company, approved acquisition of stake in Neuome Technologies Private Limited (“Neuome”). The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time is enclosed herewith as “Annexure – C”. The Board Meeting commenced at 10:45 A.M. (IST) and concluded at 01:30 P.M. (IST). We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above Annexure - A Deloitte Chartered Accountants 7th Floor Building 10 Haskins & Sells LLP Tower B DLF Cyber City Complex DLF City Phase II Gurugram-122 002 Haryana, India Tel: +91 124 679 2000 Fax: +91 124 679 2012 INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF Dr. LAL PATHLABS LIMITED 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dr. Lal PathLabs Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 ('the Statement'), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended .("the LODR Regulations"). 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (!CAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially. less in scope than an audit conducted in accordance with Standards on Auditing specified under Section· 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Statement includes the results of the following entities: a) Dr. Lal PathLabs Limited, the Parent company b) Paliwal Diagnostics Private Limited, a subsidiary company c) Dr. Lal PathLabs Nepal Private Limited, a subsidiary company d) Dr. Lal PathLabs Bangladesh Private Limited, a subsidiary company e) Dr. Lal Ventures Private Limited, a subsidiary company f) PathLabs Unifiers Private Limited, a subsidiary company g) Shahbazkers Diagnostic Centre Private Limited, a subsidiary company (w.e.f. May 01, 2026) h) Dr. Lal Pathlabs FZCO, a subsidiary company (w.e.f. June 12, 2026) i) Centrapath Labs Private Limited, a step-down subsidiary company j) APRL PathLabs Private Limited, a step-down subsidiary company k) Chanre Laboratory Private Limited, a step-down subsidiary company Regd. Office: One International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 Deloitte Haskins & Sells LLP 5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SES! (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the LODR Regulations"), including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The Unaudited Consolidated Financial Results include the unaudited financial information of four subsidiary companies which have not been reviewed by their auditors and have been approved and furnished to us by the Management, whose financial results reflect total revenue of Rupees 76.39 Million, total profit after tax of Rupees 8.66 Million and total comprehensive income of Rupees 9.76 Million for the quarter ended June 30, 2026, as considered in the Statement. Our conclusion on the Statement, in so far as it. relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited financial information certified by the Management. According to the information and explanations given to us by the Management, these financial results are not material to the Group. Our conclusion on the Statement in respect of matter stated in para 6 above is not modified with respect to our reliance on the financial results certified by the Management. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm Registration No.: 117366W/W-100018) Partner Place: Gurugram (Membership No: 95540) Date: July 24, 2026 (UDIN: 26095540WAGLZX8217) Dr. Lal Pathlabs Limited ti CIN: L74899DL1995PLC065388 Z> [Showing first 8,000 characters — download PDF for full document]